Evaluating the effects of curcumin nanomicelles on clinical outcome and cellular immune responses in critically ill sepsis patients: A randomized, double-blind, and placebo-controlled trial

Abstract

IntroductionIn sepsis, the immune system is overreacting to infection, leading to organ dysfunction and death. The purpose of this study was to investigate the impacts of curcumin nanomicelles on clinical outcomes and cellular immune responses in critically ill sepsis patients.MethodFor 10 days, 40 patients in the intensive care units (ICU) were randomized between the nano curcumin (NC) and placebo groups in a randomized study. We evaluated serum levels of biochemical factors, inflammatory biomarkers, the mRNA expression levels of FOXP3, NLRP-3, IFN-γ, and NF-κp genes in the PBMCs, and clinical outcomes before the beginning of the supplementation and on days 5 and 10.ResultsNLR family pyrin domain containing 3 (NLRP3), interferon gamma (IFN-γ), and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) mRNA expression levels significantly P = 0.014, P = 0.014, and P = 0.019, respectively) decreased, but forkhead box P3 (FOXP3) mRNA expression levels increased significantly (P = 0.008) in the NC group compared to the placebo group after 10 days. NC supplementation decreased serum levels of IL-22, IL-17, and high mobility group box 1 (HMGB1) (P < 0.05). Nevertheless, biochemical factors and nutritional status did not differ significantly (P > 0.05). NC supplementation resulted in decreased sequential organ failure assessment and multiple organ dysfunction syndromes scores, while it did not have significant impacts on length of stay in the ICU, systolic blood pressure, diastolic blood pressure, a saturation of oxygen (%), and respiratory rate (breaths/min) PaO2/FiO2 (p > 0.05).ConclusionFor critically ill patients with sepsis, NC supplementation may be an effective therapeutic strategy. More randomized clinical trials involving longer follow-up periods and different doses are needed to achieve the best results.

Revealing the role of Peg13: A promising therapeutic target for mitigating inflammation in sepsis

“…It plays a crucial function in pathological and pathophysiological processes, particularly inflammation ( Werder et al, 2022 ). Aberrant systemic inflammatory responses are characteristic of sepsis, and reducing HMGB1 has been shown to alleviate inflammation and improve patient survival ( Karimi et al, 2022 b ). Furthermore, HMGB1 in serum and urine has demonstrated excellent diagnostic efficacy for sepsis-triggered acute kidney damage ( Zang et al, 2022 ).…”

Curcumin Nanocarriers with a Focus on Cellular Uptake Studies – An Innovative Cancer Therapy

“…By changing dangerous ROS into less reactive forms, these enzymes are essential to the body's defence against oxidative stress (Bai et al2022). Curcumin increases the endurance and function of these enzymes, increasing the antioxidant capacity of cells (Karimi et al 2022). By altering signalling pathways related to redox equilibrium, Curcumin has the ability to indirectly prevent oxidative damage in addition to its direct antioxidant actions.…”

A comprehensive insight into the molecular and cellular mechanisms of action of resveratrol on complications of sepsis a systematic review

“…Sepsis is an important and complex medical disorder that occurs as an overreaction of the immune system to infection (Karimi et al, 2019; Karimi et al, 2020). Excessive immune system response to eliminate pathogens such as bacteria, fungi, viruses, and parasites can lead to organ failure, and death (Karimi et al, 2022; Yang et al, 2020). According to statistics, 31.5 and 19.4 million people, respectively, suffer from sepsis and severe sepsis each year (Karimi et al, 2021).…”